SCHEMBL5164718

SCHEMBL5164718

CCOC(=O)CN1C(=O)S/C(=C/c2ccc(-c3ccc(Cl)c([N+](=O)[O-])c3)o2)C1=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.72
KMT2A Q03164 5/20 0.72
POLB P06746 1/20 0.72
CTDSP1 Q9GZU7 1/20 0.72
TDP1 Q9NUW8 1/20 0.72
L3MBTL1 Q9Y468 1/20 0.72
ITGB2 P05107 6/20 0.67
ITGAM P11215 6/20 0.67
SLC1A3 P43003 5/20 0.65
ALDH1A1 P00352 3/20 0.59
MAPT P10636 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
USP2 O75604 1/20 0.59
LMNA P02545 1/20 0.59
HPGD P15428 1/20 0.57
CASP3 P42574 1/20 0.56
SENP8 Q96LD8 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
SENP6 Q9GZR1 1/20 0.56
PPARG P37231 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5164720 1.00 MEN1 (0.72) MEN1KMT2APOLBCTDSP1TDP1
SCHEMBL5167090 0.86 ITGB2 (0.77) MEN1KMT2APOLBCTDSP1TDP1
SCHEMBL5167082 0.86 ITGB2 (0.77) MEN1KMT2APOLBCTDSP1TDP1
SCHEMBL6392207 0.86 MEN1 (0.87) MEN1KMT2APOLBCTDSP1TDP1
SCHEMBL6392210 0.86 MEN1 (0.87) MEN1KMT2APOLBCTDSP1TDP1
SCHEMBL5145055 0.85 ITGB2 (0.74) MEN1KMT2APOLBCTDSP1TDP1
SCHEMBL5145053 0.85 ITGB2 (0.74) MEN1KMT2APOLBCTDSP1TDP1
SCHEMBL5147227 0.84 MEN1 (1.00) MEN1KMT2APOLBCTDSP1TDP1
SCHEMBL5147232 0.84 MEN1 (1.00) MEN1KMT2APOLBCTDSP1TDP1
SCHEMBL5142921 0.84 ITGB2 (0.79) MEN1KMT2APOLBCTDSP1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 MEN1 4004/4885KMT2A 4410/4885POLB 2945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.